Cell and gene therapies (C>s) have the potential to transform healthcare, but there are misconceptions held by patients, their families, and the general public that can cause fear and harm the reputation of these treatments.
The most common of these misconceptions include concerns about efficacy, side effects, and length of treatment. These fears can lead to delays in treatment and lower the chances of successful therapy outcomes.
There are also concerns about the effectiveness of C>s due to small patient populations in early clinical trials and the lack of presentation of successful results from larger clinical trials, which can provide evidence of a therapy’s overall effectiveness.
To address these issues, healthcare providers and pharma companies can provide accessible and relevant information, on-demand healthcare support, and virtual appointments to educate patients about the complexities of treatment and build trust.
It is also important for these parties to listen to patient advocacy groups and understand any gaps in knowledge or misperceptions to develop content and messaging that helps patients understand the diseases and treatments.
In our piece with The Medicine Maker, Ben Beckley, our Global Lead at EmerGENE, explores these misconceptions further. He also shares the ways pharmaceutical companies can support in ensuring patients are given the tools to make informed decisions about their C> treatments.
Read more: https://themedicinemaker.com/business-regulation/patients-be-not-afraid
Jump to a slide with the slide dots.
The decision-making process of community physicians is complex, yet gaining meaningful insights into it remains one of the most challenging aspects
Read moreAlthough individually uncommon, rare health conditions collectively affect more than 300 million people worldwide. To mark Rare Disease Day on 28 Febr
Read moreUnlock better brand performance by integrating market research, internal alignment, and real-world data for deeper insights.
Read more